Patrick Campbell

A study from e-ECE 2020 suggests thyroid inflammation could put patients at greater risk for developing an anxiety disorder.

New research suggests children treated with high-doses of oral glucocorticoids could be at a greater risk of diabetes, hypertension, and venous thromboembolism.

A meta-analysis of more than 3 dozen RCTs suggests increased intake of omega-3 supplements, such as EPA and DHA, was linked to a decreased risk of myocardial infarction action and coronary heart disease events.

Data from the WHI indicates adverse pregnancy outcomes were associated with increased risk of ASCVD later in life.

Analysis of data from a European aging study suggests feeling lonely was linked to an increased risk of developing diabetes in older adults.

An analysis of more than 1100 children suggests those born to mothers with gestational diabetes mellitus were at increased risk of accelerated aging.

Data from more than 4500 diabetics suggest CAC was better at predicting CVD and all-cause mortality in women than in men.

An interview examining the use of coronary artery calcium scores for predicting CV events and stroke risk in real-world settings.

A study published in an AHA journal describes recent trends, predictors, and outcomes of stroke in patients with hypertensive disorders of pregnancy.

New research suggests children born to mothers with PCOS could be at an increased risk of developing a psychiatric disorder later in life.

A study from ESC Congress 2020 dove deeper into associations between specific biomarkers and risk of CV events in CAD patients with and without diabetes.

Lead investigator of the PARALLAX trial discusses whether he feels clinical data related to sacubitril/valsartan is strong enough to warrant prescribing it for HFpEF patients.

An analysis from ESC Congress 2020 is shedding further light on the effects of dulaglutide in patients with and without background metformin use.

Deepak Bhatt, MD, of Brigham and Women's Hospital, offers perspective on REDUCE-IT analyses and icosapent ethyl (Vascepa) data presented at ESC Congress 2020.

Full results of DAPA-CKD further inform clinicians on dapagliflozin and use of SGLT2 inhibitors in those with and without diabetes.

An ESC Congress 2020 study details the predictive value of galectin-3 levels for predicting risk of cardiovascular events in patients with type 2 diabetes

A podcast featuring the presenter of DAPA-CKD discussing results of the trial and how they inform use of dapagliflozin in patients with chronic kidney disease with and without type 2 diabetes.

Milton Packer, MD, discusses how EMPEROR-Reduced data influences the way clinicians view the SGLT2 inhibitor class and its uses.

A podcast featuring an interview with Prof. Kausik Ray centered around the latest inclisiran data presented at ESC Congress 2020.

A study from ESC Congress 2020 details the effects of initiating rhythm control within the first year of an atrial fibrillation diagnosis.

Lead investigator of IMPACT-AFib discusses the results of the study and how they inform clinicians on strategies to improve oral anticoagulant use.

A podcast featuring the lead investigator of a recent study examining impact of metabolic syndrome on COVID-19 outcomes in a pair of New Orleans-based hospitals.

Investigators found no benefit from the discontinuation of ACE inhibitors/ARBs in patients hospitalized with COVID-19 in a prospective, randomized, phase 4 trial.

A look at the state of insulin affordability in 2020 and how the ongoing pandemic has impacted the situation.

How good are your diagnostic skills? Test them with this month's Visual Dx quiz!

The MiniMed 770G becomes the first system to receive approval for children in this age group.

The largest and most comprehensive look at blood pressure therapies and cardiovascular disease risk to date is providing an overview of the effects of antihypertensive therapy at varying levels of baseline blood pressure.

Results of HOME-PE suggest an approach using HESTIA was noninferior to sPESI for patients with acute pulmonary embolism.

Analysis of the UK Biobank cohort details associations between increased HbA1c levels and risk of myocardial infarction in patients regardless of sex.

Full results of the DAPA-CKD trial from ESC Congress 2020 detail the effects of dapagliflozin (Farxiga) among chronic kidney disease patients with and without type 2 diabetes.